USA Joshua Salsi, Head of North America, Biocon Biologics explains the company’s evolution into an integrated, global biosimilars company following the 2022 Viatris portfolio reacquisition. He highlights the company’s growing US leadership, expanding pipeline, vertical integration, and focus on patient access. Salsi goes on to stresses that long-term biosimilar growth depends…
USA Pamela Gavin, CEO of the National Organization for Rare Disorders, discusses NORD’s origins in the advocacy movement that led to the Orphan Drug Act and its current mission to improve diagnosis, care, research, and policy for rare disease patients. She highlights the growing role of patient-led research, the need for…
USA Daniel Camardo is the President of Immedica Pharma US Inc. (Immedica), the US affiliate/subsidiary of Immedica Pharma AB, a Sweden-based rare disease company that entered the American market in 2024. Bringing together his experience building Astellas’s US presence and leading rare disease commercialization at Horizon, Camardo joined Immedica to lead…
USA Gilmore O’Neill, CEO of Editas Medicine, reflects on the company’s evolution from CRISPR pioneer to focused in vivo therapeutics developer. Two years into a strategic pivot, O’Neill shares the reasoning behind discontinuing the reni-cel cell therapy program in favor of lipid nanoparticle-delivered gene editing, and how EDIT-401, targeting severe hyperlipidemia,…
USA Randy Pritchard, General Manager and Senior Vice President of Clinical Operations for North America at bioMérieux, a global leader in in vitro diagnostics, speaks about the outsized strategic weight of the North American market, which accounts for nearly half of the company’s global revenue and a third of its workforce.…
USA Leonard Paolillo, President of Merz Therapeutics North America, shares what it means to be a growing player in the specialty neurology space. Two years after the company’s acquisition of INBRIJA® (levodopa inhalation powder) and AMPYRA® (dalfampridine), and with XEOMIN® (incobotulinumtoxinA) continuing to anchor its portfolio, Paolillo reflects on how Merz…
USA Neuroscience is back. After a litany of divestments and scale backs in the 2010s, diseases of the brain are now the second-most-funded area in biotech, behind only cancer. However, this remains a complex and challenging field, leading neuroscience biotechs – three of which are profiled below – to develop very…
USA Legend is looking at all ways to bring CAR-T to more patients, including allogeneic, autologous, and in vivo approaches Alan Bash, Interim CEO of Legend Biotech speaks about achieving the milestone of treating 13,000 adult patients, with relapsed or refractory multiple myeloma who have received at least 1 prior line…
USA Our next phase of evolution is moving from pure-play generics to something more complex across branded products, biosimilars, and NCEs Punit Patel, President and CEO, of Zydus Americas, speaks about leading the company’s pivot from a pure-play generics business into complex generics, biosimilars and new chemical entities. Anchored by its…
USA Mohit Manrao, SVP and Head of US Oncology at AstraZeneca, leads the company’s effort to drive impact for cancer patients across the US. He elaborates on what it means to realise AstraZeneca’s bold ambition to eliminate cancer as a cause of death and shares how this mission goes beyond developing…
USA Chris Posner, President of Esteve Pharmaceuticals LLC, the US affiliate of Spanish specialty player ESTEVE, speaks about the process of building its US affiliate from the ground up since joining in January. With an ambition to build a 1 billion USD global business (the US is expected to drive more…
USA Dr Maisha Draves, Associate Executive Director of The Permanente Medical Group (TPMG), speaks to the group’s approach to integrating the use of biosimilars across the care network. By focusing on rigorous research evaluation and peer-to-peer education, TPMG has become a national frontrunner in the uptake of formulary inclusion and the…
See our Cookie Privacy Policy Here
